280 related articles for article (PubMed ID: 17986163)
21. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
22. Suspected opioid overdose case resolved by CYP2D6 genotyping.
Shaw KD; Amstutz U; Jimenez-Mendez R; Ross CJ; Carleton BC
Ther Drug Monit; 2012 Apr; 34(2):121-3. PubMed ID: 22406651
[TBL] [Abstract][Full Text] [Related]
23. [Problem forte--is paracetamol-codeine combination rational?].
Helland A; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2084-7. PubMed ID: 15334119
[TBL] [Abstract][Full Text] [Related]
24. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Zourková A; Hadasová E
Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
[TBL] [Abstract][Full Text] [Related]
25. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P; Ross CJ; Hayden MR; Carleton BC; Gaedigk A; Leeder JS; Koren G
Clin Pharmacol Ther; 2009 Jan; 85(1):31-5. PubMed ID: 18719619
[TBL] [Abstract][Full Text] [Related]
27. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine.
Madadi P; Koren G; Cairns J; Chitayat D; Gaedigk A; Leeder JS; Teitelbaum R; Karaskov T; Aleksa K
Can Fam Physician; 2007 Jan; 53(1):33-5. PubMed ID: 17872605
[TBL] [Abstract][Full Text] [Related]
28. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
29. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
30. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
31. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected].
de Wildt SN; Koren G
Paediatr Anaesth; 2008 Mar; 18(3):273-4; author's reply 275-6. PubMed ID: 18230076
[No Abstract] [Full Text] [Related]
32. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype.
Stamer UM; Stüber F
Anaesthesia; 2007 Dec; 62(12):1294-5; author reply 1295-6. PubMed ID: 17991273
[No Abstract] [Full Text] [Related]
33. Pharmacogenetics in palliative care.
Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
[TBL] [Abstract][Full Text] [Related]
34. [Genetic polymorphisms and human sensitivity to pain and opioids].
Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
36. Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiency.
Mörike K; Platten HP; Mikus G; Klotz U
Br J Clin Pharmacol; 1998 Jul; 46(1):87. PubMed ID: 9690955
[No Abstract] [Full Text] [Related]
37. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
Bozina N; Jovanović N; Lovrić M; Medved V
Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
40. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares OA; Fudin J; Daly AL; Boston RC
Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
